ParientiJ.J., BangsbergD.R., Verdon R., Gardner E.M. Better adherence with once-daily antiretroviral regimens: a meta-analysis // Clin Infect Dis.-2009.- Vol. 48 (4).- Р. 484-488.
Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.02; June, 2014) / European AIDS Clinical Society.- Р. 82.- URL: (http://eacsociety.org/Portals/0/140601_EACS[%]20EN7.02.pdf).http://eacsociety.org/Portals/0/140601_EACS[%]20EN7.02.pdf)
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents //Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) May 1, 2014 (http://AIDSinfo.nih.gov).http://AIDSinfo.nih.gov)
MollanK.R., SmurzynskiM., EronJJ., DaarE.S., Campbell T.B., SaxP.E., GulickR.M., Na.L, O'Keefe L., RobertsonK.R., Tierney. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data // Annals of Internal Medicine.- Vol. 161 (1).- Р 1 - 10.
Cohen C., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial // Lancet.- 2011.- Vol. 378.- P. 229-237. doi: 10.1016/S0140 - 6736(11)60983-5..
DOI: 10.1016/S0140 - 6736(11)60983-5
Molina J-M., CahnP., GrinsztejnB., LazzarinA., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., BovenK. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial // Lancet.- 2011.- Vol. 378.- P. 238 - 246. (doi: 10.1016/S0140-6736(11)60936-7)..
DOI: 10.1016/S0140-6736(11)60936-7)
Кравченко А.В., Канестри В.Г. Опыт применения препарата рилпивирин в схемах антиретровирусной терапии больных ВИЧ-инфекцией в России // Инфекционные болезни, 2013.- Т. 11, № 3.- С. 55-60.
Cohen C., WohlD., ArribasJ., Henry K., van LunzenJ., BlochM., Towner W., Wilkins E., EbrahimiR., Porter D., White K., Walker I., Chuck, S., De-Oertel S., Fralich T. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults // AIDS.- 2014.- Vol. 28 (7).- Р 989-997.
Cohen C., Wohl D., Arribas J., Henry K., van Lunzen J., Bloch M., Towner W., Wilkins E., Ebrahimi R., Porter D., Patel K., De-Oertel S., Fralich T., Guyer B. STaR Study: Single Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naive Adults through Week 96// 14th European AIDS Conference, October 16-19, 2013, Brussels, Belgium.- Abstr. LBPE7/17 www.EACS-CONFERENCE2013.COM
AiroldiM., ZaccarelliM., BisiL., Bini Т., AntinoriA., Mussini C., BaiF., Orofino G., SighinolfiL., GoriA., SuterF., MaggioloF. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects // Patient Prefer Adherence.- 2010.- Vol. 4.- Р. 115-125.
Palella Jr F.J., Fisher M., TebasP., Gazzard B., Ruane P., Van LunzenJ., Shamblaw D., FlammJ., EbrahimiR., Porter D., White K., HindmanJ., Elbert E., De-Oertel S., Fralich T. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants // AIDS.- 2014.- Vol. 28, № 3.- Р. 335-344.
SanfordM. Rilpivirine // Drugs.- 2012.- Vol. 73 (4).- P. 525 - 541.